Phase II trial of IPH 2201 monotherapy in patients with metastatic or recurrent platinum refractory squamous cell carcinoma of the head and neck.
Phase of Trial: Phase II
Latest Information Update: 19 Feb 2015
Price : $35 *
At a glance
- Drugs Monalizumab (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- Sponsors Innate Pharma
- 19 Feb 2015 According to Innate Pharma media release, first patient in this trial was treated in December 2014.
- 19 Feb 2015 According to Innate Pharma media release, status changed from not yet recruiting to recruiting.
- 17 Apr 2014 New trial record